羟基脲作用机制 - Medchemexpress - MCE中国

1、Product Data SheetHydroxyureaCat. No.: HY-B0313CAS No.: 127-07-1分式: CHNO分量: 76.05作靶点: DNA/RNA Synthesis; Autophagy; Apoptosis; HIV作通路: Cell Cycle/DNA Damage; Autophagy; Apoptosis; Anti-infection储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (1314.92

2、mM; Need ultrasonic)H2O : 50 mg/mL (657.46 mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 13.1492 mL 65.7462 mL 131.4924 mL5 mM 2.6298 mL 13.1492 mL 26.2985 mL10 mM 1.3149 mL 6.5746 mL 13.1492 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -2

3、0C, 1 month。-80C 储存时，请在 6 个内使，-20C 储存时，请在 1 个内使。体内实验请根据您的实验动物和给药式选择适当的溶解案。以下溶解案都请先按照 In Vitro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/m

4、L (32.87 mM); Clear solution此案可获得 2.5 mg/mL (32.87 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 25.0 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (32.87 mM); Clear solutionPage 1 of 2 www.MedChem

5、E此案可获得 2.5 mg/mL (32.87 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 25.0 mg/mL 的澄 DMSO 储备液加到 900 L 20% 的 SBE-CD 理盐溶液中，混合均匀。3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (32.87 mM); Clear solution此案可获得 2.5 mg/mL (32.87 mM，饱和度未知) 的澄 溶液，此案不适于实验周 期在半个以上的实验。以 1 mL 作液为例，取 100 L 25.0 mg/mL 的澄 DMSO 储备液加到

6、 900 L 油中，混合均匀。BIOLOGICAL ACTIVITY物活性 Hydroxyurea 通过抑制核糖核苷酸还原酶抑制 DNA 合成的细胞凋亡诱导剂。体外研究 Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases1. Treatmentof cells in primary culture with 30 M hydroxyurea for 96 hours significantly increases the fractional

7、 HbF content. TheG: A-globin mRNA is induced 0.30- to 8-fold in vitro2. Hydroxyurea has been shown to block HIV-1 reversetranscription and/or replication in quiescent peripheral blood mononuclear cells and macrophages3.体内研究 Hydroxyurea therapy producs consistent reductions in WBC and ANC without imp

8、rovement in anemia over 17 weeks.Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvementin anemia compared to vehicle treated sickle cell mice4.PROTOCOLAnimal Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish

9、 the development ofAdministration 4 organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, orvehicle is administered five days per week to SCD mice4.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品

10、发表的科研献 J Mol Med (Berl). 2019 Aug;97(8):1183-1193. J Cell Mol Med. 2019 Jul 23.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical a

11、pplications.Med Hypotheses. 2011 Jan;76(1):24-31.2. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. ExpHematol. 2005 Dec;33(12):1486-92.3. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human

12、 immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.Page 2 of 3 www.MedChemE4. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010Sep;95(9):1599-603.McePdfHeightCaution: Product has not been fu